A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

Shanghai Tongji Hospital, Tongji University School of Medicine13 enrolled

Overview

This is a single-center, non-randomized clinical study to evaluate the safety and efficacy of C-CAR066 in treatment of r/r B cell lymphoma who received CD19 CAR-T therapy.

This study plans to enroll 10 patients to assess the safety and efficacy of C-CAR066. Subjects who meet the eligibility criteria will receive a single dose of C-CAR066 injection. The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR066 infusion and Follow-up Visit.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

B Cell Lymphoma

Interventions

CD20-directed CAR-T cells with CliniMACS Prodigy® systemBIOLOGICAL

Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. The patient volunteered to participate in the study, and signed the Informed Consent 2. Age 18-70 years old, male or female 3. Patients with CD20+ DLBCL (including PMBCL and tFL), FL and MCL, at least one measurable lesion (LDi≥ 1.5 cm) 4. r/r lymphoma patients who received prior CD19 CAR-T therapy 5. At least one week from last treatment (radiation, chemotherapy, mAb, etc) to apheresis 6. No immunosuppressive therapy was used within 1 week before C-CAR066 infusion 7. No mAb treatment within 2 weeks before C-CAR066 infusion 8. Adequate organ and bone marrow function 9. No contraindications of apheresis 10. Expected survival time \> 3 months 11. ECOG scores 0-1 Exclusion Criteria: 1. Have a history of allergy to cellular products 2. Patients with cardiac insufficiency classified as Class III or IV according to the New York Heart Association (NYHA) Heart Function Classification Standard 3. A history of craniocerebral trauma, consciousness disorder, epilepsy, cerebral ischemia or hemorrhagic cerebrovascular disease 4. Patients with active CNS involvement 5. Patients with autoimmune disease, immunodeficiency, or other treatment requiring immunosuppressor 6. Severe active infection (except simple urinary tract, bacterial pharyngitis), or currently receiving intravenous antibiotics. However, prophylactic antibiotics, antiviral and antifungal treatments are allowed 7. Live vaccination within 4 weeks before apheresis 8. HIV, HBV, HCV and TPPA / RPR infections, and HBV carriers 9. Have a history of alcoholism, drug addiction and mental illness 10. Non-sterile subjects had any of the following: a) being pregnant / lactating; or b) having a pregnancy plan during the trial; or c) having fertility without taking effective contraception 11. Patients with severe fludarabine or cyclophosphamide hypersensitivity 12. The patient has a history of other primary cancers, except for the following: 1. Non-melanoma such as skin basal cell carcinoma cured by resection 2. Cured carcinoma in situ such as cervical, bladder or breast cancer 13. The investigators believe that there are other circumstances that are not suitable for the trial

Locations (1)

Shanghai Tongji Hospital, Tongji University School of Medicine

Shanghai, China

Outcomes

Primary Outcomes

Incidence of adverse events

The incidence of treatment-emergent adverse events (TEAEs)

Time frame: Up to 12 weeks after C-CAR066 infusion